

vision.

To understand the brain, in health and illness, to improve lives and achieve societal impact.

mission.

Brain Canada is achieving its vision by:

- Increasing the scale and scope of funding to accelerate the pace of Canadian brain research;
- Creating a collective commitment to brain research across the public, private and voluntary sectors; and
- Delivering transformative, original and outstanding research programs.

values.

- Connecting with purpose.
 - "One brain". Seeking to understand different brain functions and dysfunctions as part of a single interconnected system.
 - Partnerships. Building mutually beneficial and transparent relationships with every partner.
 - Diverse perspectives and approaches. Fostering original insights and outcomes.
- Outcome focused. Delivering value and benefits with efficiency and effectiveness.
- Professional integrity. Ensuring the highest standards of ethical behaviour and good governance.



@BrainCanada



linkedin.com/company/braincanada



facebook.com/brain.canada



plus.google.com/103221460739825079396

table of contents.

3	į			1
	b	Ė		
		H	ė	

Highlights 2014	2
Message from the Chair and President	4
Brain Canada	6
One brain. One community.	8
Canada Brain Research Fund	10
Working with Government	11
Brain Canada research program	12
International review process	13
Multi-Investigator Research Initiative (MIRI)	14
Platform Support Grants (PSGs)	16
Training Awards	18
Our partners	20
Strategic partnerships	22
Brain philanthropists	24
Other partnerships	26
Brain Canada in the world	27
Thanks to our supporters	28
Board of Directors	29
Science Advisory Council	30
Thanks to Allan R. Taylor	31
Financial Report	32



Brain Canada Foundation 1200 McGill College Avenue Suite 1600 Montreal, Quebec H3B 4G7

to the first to th

Tel: 514.989.2989 info@braincanada.ca

Partnership Registration number: 86870 6326 RR0001 Foundation Registration number: 89105 2094 RR0001

The Brain Canada Foundation (referred to throughout as "Brain Canada") is a national, charitable organization.

Photos

Cover, page 4, 24 bottom and 31, Teddy Chau

Page 11 top, Owen Egan, Courtesy of McGill University

Page 11 bottom, Katie Cooper, Medical Media Centre, St. Michael's Hospital

Page 14 Andrew Nguyen, Lemongrass Films, Courtesy of Genome BC

Page 16 Owen Egan, Courtesy of McGill University

Page 18 top, Owen Egan

Page 22 bottom, Aura McKay Photography, Courtesy of Genome BC

Page 23 top, Martine Frigon, courtesy of CQDM and Canadian Association for Neuroscience

highlights 2014.

canadian cancer society

Initiated a partnership to support Canadian Cancer Society Impact Grants focused on brain and nervous system cancer research.

Announced a partnership with the Hotchkiss Brain Institute as part of the 2014 MIRI Sponsored Opportunity - \$3 M to co-fund two teams with at least one focused on mental health.

alberța partnership



Inez Jabalpurwala joined world leaders and presented the Brain Canada model at the Global Dementia Event in London, UK.

london, UK

Announced \$51.4 M for funding of 32 groundbreaking projects through the 2014 MIRI and PSG programs with Health Minister Rona Ambrose.



february 7 may 26 june 19 may 1 **may 12** september 11 september 12 october 7

Prime Minister Stephen Harper, along with members of the Chaqnon Family and Azrieli Foundation, and representatives from Brain Canada. announced the support of five new projects in the areas of Alzheimer's disease, autism and Fragile X syndrome.



cqdm/obi/brain

Launched the Focus on Brain program, a CODM/ OBI/Brain Canada partnership open to multidisciplinary research teams linking Canadian researchers to small and medium-sized enterprise sectors.



Inez Jabalpurwala introduced the Health Minister Rona Ambrose, at the 2014 Canada-France Global Dementia Event in Ottawa, ON.

ottawa, canada

Hotchkiss institute

Announced \$7.4 M in funding to support six brain and mental health projects in Alberta.





Inez Jabalpurwala was a panelist at "Changing the Global Care for Alzheimer's and Dementia" hosted by AARP.

The Barbara Turnbull Award honoured top spinal cord researcher Dr. Yves De Koninck.



Barbara Turnbull Award



Announced the BC Alzheimer's Research Award with Genome BC. MSFHR and PARF to fund five projects totaling \$7.5 M.

five projects

october 10

october 22

november 7

november 19

november 21

december 15

Initiated a partnership with Alzheimer's Society to launch "New Investigator and Career Change" grant.

alzheimer's society partnership

\$20M **ALS** partnership

Announced \$20 M partnership with ALS Canada to match funds raised from Ice Bucket Challenge for ALS research.



Launched 2015 Team and Platform Support grants, and Phase II of Azrieli Neurodevelopmental Research Program Request for Applications.

Team and **Platform** Support Grants

message from the chair and president.



There has never been a more exciting time to be part of the brain community.

Understanding the brain and brain diseases is a complex endeavor, requiring researchers from a range of science disciplines and clinical areas to collaborate in new ways. Equally important is the involvement of patients, families, caregivers, voluntary health organizations, business leaders, philanthropists and governments. They drive priorities and create a sense of urgency in moving research from novel ideas to outcomes that will benefit people.

The theme of this year's annual report, "one brain. one community." captures both Brain Canada's one system approach to understanding the brain—recognizing common mechanisms among the range of neurological diseases and disorders, mental illnesses, addictions, brain and spinal cord injuries—and the many people and organizations working as one community to accelerate progress.

Since launching the Canada Brain Research Fund in May 2012, Brain Canada and the Government of Canada have partnered to lead a transformation of brain research in this country. resulting in a more coordinated, collaborative brain community within Canada and with the rest of the world. This has included dialogue with leading Canadian and international scientists, and nationwide consultations with our stakeholders.

We are proud to report that, to date. Brain Canada's donors and 59 partners—including research institutes, provincial agencies and voluntary health organizations—have committed more than \$85 million towards our \$100-million goal. a dramatic increase from the \$45 million reported in our 2013 Annual Report. This is well ahead of our timeline to close the campaign by March 2017. The funds are being matched by the Government of Canada on a 1:1 basis and, of the total, we have already awarded more than \$106 million to support 77 research projects involving 406 researchers across 67 institutions. All projects were selected further to national, open calls and international peer review. When looking at our growth, keep in mind that the Government of Canada is providing about \$129 million per year for neuroscience research through its granting councils. The Brain Canada-Government partnership is therefore adding significantly to funding available to support excellent and innovative Canadian brain research.

The 77 projects we are currently funding cover a range of approaches to understanding brain function and dysfunction. These include:

• Using the latest imaging technology to map brain development and wiring;

- Dissecting the molecular underpinning of addictions and movement disorders;
- Constructing novel proteins to deliver drugs across the blood-brain barrier:
- Using bioengineering approaches to restore vision;
- Expanding a national biobank and database for patients with traumatic brain injury;
- Uncovering the interplay of genes regulating dopamine neuron degeneration in Parkinson's disease;
- Investigating the multifaceted influence of environmental conditions during development on mental health outcomes;
- · Developing a novel intervention to prevent onset of Alzheimer's disease by combining cognitive therapy and noninvasive brain stimulation:
- Building the infrastructure for Canada's most comprehensive brain bank with over 3,000 samples from patients with diverse neurological and mental disorders.

Our cover features members of one of the teams that was awarded a grant in 2014. The Frontier Trial project, led by Dr. Laurie Morrison of University of Toronto, is bringing together neurologists, neuroscientists, biostatisticians and emergency medicine specialists from across Canada, to test a drug that can be administered by paramedics, aimed at reducing the devastating damage caused by stroke by up to 50%. This is just one example of "one brain. one community." in action, from basic research to patient care.

There has never been a more exciting time to be part of the brain community. We thank all of our supporters over the past year, especially the Government of Canada, and our dedicated Board and staff. In the coming year, we look forward to reaching our \$100-million goal and celebrating our \$200-million partnership with Government. This is the largest public-private partnership in Canadian history devoted to brain research. We will then set our sights on increasing this investment to meet the capacity of our world-class researchers who are working to unlock the mysteries of the brain, to the benefit of all Canadians.

Rupert Duchesne
Chair, Brain Canada


Inez Jabalpurwala
President and CEO, Brain Canada

brain canada.

Brain Canada is a national non-profit organization headquartered in Montreal, Quebec, that enables and supports excellent, innovative, paradigm-changing brain research in Canada. For more than one decade, Brain Canada has made the case for the brain as a single, complex system. Looking at the brain as one system has underscored the need for increased collaboration across disciplines and institutions, and a smarter way to invest in brain research that is focused on outcomes that will benefit patients and families.




Research Types Funded




Stimulating increased awareness and investment in brain research.

Yearly Research Commitment



Provincial Distribution of Projects



Bringing the best minds together—new thinking, new approaches.

one brain. a systems approach.

The brain is the most critical organ in the body, but the least understood. Brain disorders impact 1 in 3 Canadians and impose a \$60 billion burden on the Canadian economy every year – an impact that is greater than cancer and cardiovascular disease combined.

There are about 1,000 diseases, disorders and injuries of the brain and nervous system. These disorders can occur at any stage in life.

There are commonalities across these conditions, such as cell loss, abnormal functioning of nerve cells, and chemical and molecular imbalances in the brain. Looking at the brain as one system can lead to breakthroughs that will have impact on multiple conditions.


depression alzheimer's disease brain tumours schizophrenia parkinson's disease multiple sclerosis autism epilepsy chronic pain bipolar disorder addiction memory impairment brain damage spinal cord damage post-traumatic stress

A systems approach – One brain

- enabling innovative, integrated and collaborative brain research;
- across disciplines and institutions;
- and on a range of diseases, disorders and injuries.

one community.

Collectively, the diseases of the brain are the major health challenge of the 21st century. The burden that brain disorders pose on society requires a consolidated and strong commitment of support from the global community. Over the past few years, world leaders, patient advocates, scientists and major philanthropists have realized this and risen to the challenge, bringing unprecedented attention and resources to accelerate the pace of brain research aimed at understanding brain function and dysfunction.




"One brain. One community. captures the spirit and the state of brain research: a global quest to understand the brain, across disciplines, across sectors, and across countries. I am exhilarated by the community that has come together to work towards preventing, diagnosing, treating, and one day curing brain disorders—the major health challenge of our time. And I am proud of Canada's contributions to this effort."

- Inez Jabalpurwala, President and CEO, Brain Canada

canada brain research fund.

The Canada Brain Research Fund (CBRF) is a public-private partnership (PPP) designed to encourage Canadians to increase their support of brain research, and maximize the impact and efficiency of those investments. Brain Canada committed to raising \$100 million from private and non-governmental sources, which is being matched by Government on a 1:1 basis, up to \$100 million over six years (2011–2017).

This visionary commitment by the Government of Canada will ensure that Canada continues to be among the leaders in the global challenge to understand brain function and brain diseases.



Business approach to science: outcome-focused, efficient.

working with government.

Since the establishment of the Canada Brain Research Fund in 2011, Brain Canada and the Government of Canada have been working in partnership to fund brain research that has the best potential of making a real impact on the lives of Canadians.

May 1st, 2014

Prime Minister Stephen Harper, along with members of the Chagnon Family and Azrieli Foundation, and representatives from Brain Canada, announced the support of five new projects in the areas of Alzheimer's disease, autism and Fragile X syndrome.

"These exceptional gifts will provide critical funding and because of the public-private partnership between your foundations, Brain Canada and our Government, the impact of your investments will be doubled. That's what I call a win-win situation."

- The Rt. Hon. Stephen Harper, Prime Minister of Canada



From left to right: Mr. André Chagnon; Dr. Naomi Azrieli; Dr. Benoit Mulsant, Centre for Addiction and Mental Health; The Rt. Hon. Stephen Harper; Dr. Nahum Sonenberg, McGill University.

September 12th, 2014

The Honourable Rona Ambrose, Minister of Health, announced the joint funding of 17 Platform Support Grants (PSGs) and 15 Multi-Investigator Research Initiative (MIRI) projects, which represent a total investment of more than \$51 million over three years. The projects and platforms cover research areas such as neurodegeneration, mental health, stroke, traumatic brain and spinal cord injury, and vision restoration.

"The Fund supports the very best Canadian neuroscience research and accelerates discoveries to improve the health and quality of life for Canadians who suffer from brain disease and mental disorders."

- The Honourable Rona Ambrose, Minister of Health



From left to right: Dr. Laurie Morrison, Clinician Scientist at St. Michael's Hospital; Dr. Arthur S. Slutsky, VP of Research at St. Michael's Hospital; Dr. Xiao-Yan Wen, Scientist at St. Michael's Hospital; The Hon. Rona Ambrose, Minister of Health.

research program.


A national research-funding program that fosters collaboration and leads to transformative and original insights.

The Canada Brain Research Fund is supporting three types of programs:

- MIRI team grants;
- platform support grants;
- training awards and mentorship.

Grants are awarded to teams showing:

- Innovation and originality;
- Multidisciplinarity and teamwork;
- Potential for impact;
- · Feasibility.



Dr. James Johnson

University of British Columbia

Recipient of a 2014 MIRI team grant for a project entitled Locally produced brain insulin in memory and Alzheimer's disease: A multi-disciplinary approach to a key question.

Research focused on outcomes to benefit patients and families.

international review process.

Funding recipients are selected through open and partnered competitions and rigorous international peer review. Brain Canada funding is allocated, first and foremost, on merit. Only applications judged to be above the high standard of excellence set by the relevant selection committees are funded.

> Open National Call targeting research institutes, universities, hospitals and voluntary health organizations.

STAGE 1 Letter of Intent (LOI) Teams submit LOIs briefly describing the project.

LOIs are evaluated and scored by an International Selection Committee, benchmarked against global standards of excellence and innovation.

LOIs scoring above a threshold and deemed meritorious are recommended to advance to Full Application stage.

Invited teams submit Full Applications.

Full Applications are evaluated and scored for excellence, innovation Committee and two external reviewers with subject-matter expertise.

Full Applications deemed excellent by the International Selection Committee are recommended to Brain Canada and its partners for funding.


STAGE 2 Full **Application**

All applicants are notified of the results and provided detailed feedback.

All recommended applications are required to provide proof of institutional approval for safety, ethics and animal protocols prior to funding release.

Funding commences.

Benchmarked against international standards of excellence and innovation through consultation and peer review.



Multi-Investigator Research Initiative (MIRI)

MIRI grants support the direct operating costs of research and are awarded to proposals from multidisciplinary teams of investigators undertaking innovative and excellent research with high potential for impact.

Highlights of 2014 competition

- 52 applications were received;
- · 28 teams invited to submit full applications;
- 15 grants were recommended for funding;
- Funding totaled almost \$30 million for the 2014 competition;
- To date, funding through the MIRI program has totaled \$63 million;
- · Third MIRI competition was launched in December 2014.

Novel Retinal Biomarkers for Alzheimer's Disease

Detecting the beginning of Alzheimer's disease in an individual is difficult as the changes in behavior are subtle and hidden. Early and accurate diagnosis is the key to successful treatment. Imaging can show that a brain is filled with a protein called amyloid, which accumulates beyond normal limits in Alzheimer's. However, brain imaging exams for amyloid are expensive, can be invasive, and are not widely available. Some studies have suggested that amyloid also accumulates in the retina of individuals with Alzheimer's.

Dr. Beg is leading a team of nine researchers to collaboratively develop a new retina imaging device, which uses laser light to show the presence of amyloid in the retina. Their work could lead to an inexpensive, non-invasive and widely deployable retinal exam that could be used to screen individuals on a regular basis for the earliest signs of amyloid indicative of Alzheimer's.

Strengthening the neuroscience research community by increasing collaborations among multidisciplinary researchers and decision-makers.

2014 MIRI Team Grant Recipients

Team Leads

Jean Addington, Hotchkiss Brain Institute, University of Calgary Adolescent Mental Health

Jaideep Bains. University of Calgary Understanding stress to improve mental health

Mirza Faisal Beg, Simon Fraser University Novel retinal biomarkers for Alzheimer's disease

Rod Bremner, Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital Stimulating endogenous regeneration of photoreceptors as a potential cure for blindness

Neil Cashman, Brain Research Centre, University of British Columbia

Targeting amyloid propagation in Alzheimer disease: Structures, immunology and extracellular vesicle topology

Ann Marie Craig, Brain Research Centre, University of British Columbia

Targeting the synaptic pathway in neurodevelopmental and psychiatric disorders

Zafiris Daskalakis, Centre for Addiction and Mental Health Canadian rTMS Treatment and Biomarker Network in Depression (CARTBIND) Trial

Doris Doudet, University of British Columbia Neurobiological correlates of TMS

James Johnson, University of British Columbia Locally produced brain insulin in memory and Alzheimer's disease: A multi-disciplinary approach to a key question

Brian Kwon, University of British Columbia Biomarkers for crossing the translational divide in acute spinal cord injury

Kari Hoffman, York University

Modulating memory circuits: focal DBS treatments to improve medial temporal lobe function

Jeffrey Mogil, McGill University

Distinct neuro-immune interactions drive sex differences in chronic pain

Laurie Morrison, University of Toronto

The Frontier Trial - Field Randomization of NA-1 Treatment in Early Responders

Christian Naus, University of British Columbia Validation of connexins and pannexins as a target for Alzheimer's disease

David Vocadlo, Simon Fraser University Preclincal development of a disease modifying small molecule therapy for Alzheimer disease

* For the full list of team members for each project, please visit www.braincanada.ca/MIRI



Platform Support **Grants** (PSGs)

PSGs are designed to sustain and enhance the capabilities and accessibility of research platforms essential for tomorrow's brain research.

The grants are intended to fill a funding gap for operations and maintenance of major research platforms that provide national or regional technical capability to multiple neuroscience investigators from a number of institutions.

Highlights of 2014 competition

- 31 applications received;
- 17 PSGs team funded;
- Funding totaled just over \$27 million for the 2014 competition.

CBRAIN: Canadian Brain Research And Informatics Platform

Advances in neuroimaging over the past several years have provided researchers with unprecedented access into the inner workings of the brain. Such data can be collected non-invasively from human subjects so that dynamic changes in brain and behavior can be captured during normal development, aging, learning and plasticity. However, the collection and analysis of such detailed information requires an enormous amount of data and processing capacity. Dr. Evans and his team have developed the Canadian Brain Imaging Research Platform (CBRAIN), a web portal that provides researchers with the tools to overcome the large-scale data processing challenges of neuroimaging. The platform connects 300+ researchers in brain imaging centres across Canada and around the world, enhancing the ease with which researchers can share complex 3D and 4D brain imaging data collected from large multi-centre research projects. The platform is currently being used to uncover the underpinnings of key neurological disorders impacting society, including autism, Alzheimer's disease, Parkinson's disease and multiple sclerosis. Beyond this, CBRAIN provides a framework that can be configured to accept and analyze data from any discipline, in line with Dr. Evans' ultimate goal of establishing Canada as a global hub for "big data" research into the normal and abnormal brain.

2014 PSG Grant Recipients

Team Leads

Christopher Anderson, University of Manitoba Manitoba Neuroimaging Platform

Yves De Koninck, Université Laval The Canadian Neurophotonics Platform

Simon Duchesne, Université Laval

Le Consortium d'Imagerie en Neurosciences et santé mentale de Québec : leader régional en neuroimagerie humaine

Jeff Dunn, University of Calgary

The Experimental Imaging Centre: a Local Brain Canada Platform for Preclinical MR Neuroimaging

Alan Evans, Montreal Neurological Institute and Hospital, McGill University

CBRAIN: Canadian Brain Research And Informatics Platform

Chester Ho, University of Calgary Building the Rick Hansen Alberta Spinal Cord Injury Registry

Jamie Hutchison, The Hospital for Sick Children A National biobank and database for patients with traumatic brain injury

Deborah Kurrasch and Jong Rho, University of Calgary A Novel Zebrafish-Based Platform for Anticonvulsant Drug Development

Gregory Lodygensky, Sainte-Justine University Hospital Research Centre

The Canadian Neonatal Brain Platform

Art Petronis, Centre for Addiction and Mental Health The Ontario Brain Epigenomics Platform

Jack Puymirat, Université Laval Human inducible pluripotent stem cells (iPSC) platform

Amir Shmuel, Montreal Neurological Institute and Hospital, McGill University Montreal Functional Brain Imaging Platform

Karun Singh, McMaster University

A research platform to study animal and human cellular models of neurological disorders


Gustavo Turecki, Douglas Hospital Research Centre Douglas-Bell Canada Brain Bank, an essential platform for brain research in Canada

Fidel Vila-Rodriquez, University of British Columbia Integrated Neurostimulation Platform for Neuropsychiatric Research

Patrick Whelan, University of Calgary Regeneration Unit in Neurology: A platform for research and training in advanced microscopy and behavioural approaches

Xiao-Yan Wen, St. Michael's Hospital Z-BRAIN: A Zebrafish Drug Screening Platform Targeting Brain Disorders

* For the full list of team members for each project, please visit www.braincanada.ca/platform_support_grants



rising stars in the canadian brain research community.



Training Awards

Brain Canada's Training Awards are designed to promote the next generation of Canadian neuroscience researchers by providing them with guidance, mentorship and training under the direction of world-leading researchers. The awards are given to outstanding doctoral and postdoctoral fellows conducting innovative research to uncover the origins and consequences of neurological and/or psychiatric diseases and conditions.

Mr. Ian Gerard

For patients undergoing an operation to remove a brain tumour, image guidance in the form of a neuronavigation system is commonly used. These systems are analogous to a GPS for the brain where images are used to guide a surgeon to a specific target. A major drawback of these systems is the loss of accuracy throughout the surgery due to brain movement during the operations, making the GPS unreliable. Mr. Gerard's research aims to solve this problem through the use of intraoperative ultrasound imaging (iUS). After acquiring these new real-time images using iUS, the original images can be warped to match the new shape of the brain and the neuronavigation system becomes reliable once again. In addition, through a visualization technique called augmented reality, Mr. Gerard's work will also enable surgeons to look beyond the visible surface of the patient. By providing a surgeon with highly accurate and enhanced visualization tools the research will allow surgeons to perform more complicated surgeries with greater confidence while maintaining minimal invasiveness.

Highlights

- · Launched in 2012;
- · 7 Bell Mental Health Research Awards;
- 7 Brain Canada-CIBC Brain Cancer Research Training Awards;
- Fellowships: \$50,000/yr plus \$5,000/yr career development supplement;
- Studentships: \$30,000/yr plus \$3,000/yr career development supplement;
- Total award support: \$1.7 million over three years.

Dr. Guang Yang

Autism is a spectrum of closely-related neurodevelopmental disorders that affect one out of 68 children. While the causes of autism are unknown, perturbations in certain genes, that may be important for brain function, have been identified in some children with autism. Understanding how these autism-related genes work in the brain can provide important insights into autism and potential therapeutic strategies. Dr. Yang's research focuses on the developing brain at an early embryonic stage when neurons, the basic working unit of the brain, are being produced from their parental cells, called neural stem cells. He has helped discover that the number of neurons made from neural stem cells is altered by genetic defects in some of these autism-related genes. This early alteration during brain development disrupts normal brain structure and may thus lead to behavioural and cognitive deficits. Strategies targeting this early component of brain development may have therapeutic value for treating autism.

Training Award Recipients

Bell Mental Health Research Training Awards

FELLOWSHIPS

Steven A. Connor, University of British Columbia Characterization of the role of LRRTMs in synaptic plasticity and memory formation

Cornelia Walther, Western University CRF receptor-mediated sensitization of 5-HT2A receptor signalling

Guang Yang, Hospital for Sick Children The role of translational control in cortical dysgenesis in mammalian brain

STUDENTSHIPS

Corey Baimel, The University of British Columbia/ Hotchkiss Brain Institute – University of Calgary The effects of optogenetically activated orexin/hypocretin neurons on the mesolimbic reward pathway

Nancy Butcher, University of Toronto Antipsychotic treatment in a genetic subtype of schizophrenia: Novel insights from neuroimaging and pharmacogenetics

Jennie Pouget, Centre for Addiction and Mental Health The role of immune genes in schizophrenia

Andrea Tyrer, Centre for Addiction and Mental Health Season, light exposure and serotonin transporter binding

Brain Canada-CIBC Brain Cancer Research Training Awards

FELLOWSHIPS

Deena Gendoo, The Hospital for Sick Children Drug repurposing in medullo-blastoma using integrated functional genomic, epigenomic, and transcriptomic approaches

Nadine Richard, Princess Margaret Hospital Validation of cognitive rehabilitation program adapted to the needs of adults with brain cancer and adult survivors of childhood brain cancer

Katherine Rowland, The Hospital for Sick Children Role of YAP/Hippo and Wnt signaling in human gliomagenesis and glioma tumour-initiating cells

STUDENTSHIPS

Vincy Chan, University of Toronto

The profile and trajectory of brain tumours across the continuum of care in Ontario, Canada: A population based study

lan Gerard, Montreal Neurological Institute and Hospital, McGill University

Nonlinear MR-ÚS registration for image guide neurosurgery of brain tumours

Nishani Rajakulendran, University of Toronto Wnt signalling circuits in glioma progression

Mohini Singh, McMaster University Identification of brain metastasis initiating cells and regulators of brain metastasis from lung cancer

our partners.

In addition to our private and corporate donors, Brain Canada is deeply grateful to the following partners:

Voluntary Health Organizations

Alberta Paraplegic Foundation

ALS Society of Canada

Alzheimer Society of Canada

Canadian Cancer Society

Heart and Stroke Foundation of Canada

The Marigold Foundation

Provincial Agencies

Alberta Innovates Health Solutions

Capital District Health Authority

Fonds de recherche du Québec - Santé (FRQS)

Genome BC

Manitoba Health Research Council

Michael Smith Foundation for health Research (MSFHR)

Network of Applied Medical Genetics (RMGA)

Ontario Neurotrauma Foundation (ONF)

Ontario Brain Institute (OBI)

Pacific Alzheimer Research Foundation (PARF)

Quebec Pain Research Network

Corporations

Atuka, Inc.

Eli Lilly & Company

Life Chemicals, Inc

Treventis

Research Network

Canadian Stroke Network

Other Agencies

CODM

Institutions

Alberta Children's Hospital Research Institute (ACHRI)

Baycrest

BC Children's Hospital BioBank

Centre de Recherche Institut universitaire de gériatrie de Montréal (CRIUGM)

Centre for Addiction and Mental Health (CAMH)

Centre for Heart Lung Innovation, UBC and St. Paul's Hospital

Centre hospitalier de l'Université de Montréal (CHUM)

Children and Women's Hospital (C&W) - CFRI and UBC

CHU Sainte-Justine Foundation

CRCHUS, Université de Sherbrooke

Dalhousie University

Djavad Mowafaghian Centre for Brain Health

Douglas Hospital Research Centre

Hotchkiss Brain Institute

International Collaboration On Repair Discoveries (ICORD)

Institut universitaire en santé mentale du Québec (IUSMQ) Le Réseau québécois sur le suicide, les troubles de l'humeur et les troubles associés (RQSHA)

McGill University

McMaster University

Montreal Neurological Institute and Hospital

St. Michael's Hospital

The Hospital for Sick Children

Toronto General & Western Hospital Foundation

UBC Mental Institute of Health

Université de Montréal

Université Laval

University Health Network

University of Alberta

University of British Columbia

University of Calgary

University of Manitoba

University of Ottawa Brain and Mind Research Institute (UOBMRI)

University of Saskatchewan

University of Western Ontario

Vancouver Coastal Health Authority (VCHA)


York University

59 partners

partnerships.

Partnerships are a central component of the Canada Brain Research Fund (CBRF) and Brain Canada is committed to working with funding partners with interests across the entire range of neurological diseases and injuries, mental illnesses and addictions. We are proud to count more than 50 research institutions, provincial agencies and voluntary health organization as strategic, intellectual and financial partners—resulting in a more coordinated, collaborative brain community. Together we will have an impact on the lives of all Canadians by enabling our researchers and clinicians to make paradigm shifts that will benefit millions of people around the world.

In the coming pages we highlight just a few of our many valued partnerships, but would like to take this opportunity to thank and acknowledge all of our partners, from long-standing to most recent.



Building strong and lasting partnerships based on mutual respect and benefits.

strategic partnerships.

ALS Partnership - Ice Bucket Challenge

A partnership between the ALS Societies and Brain Canada has resulted in the largest one-time investment in the ALS Society of Canada's research program history. This partnership is leveraging taxpayer's

- Double the \$10 million directed to research from the Ice Bucket Challenge, for a combined \$20-million investment in a national research program;
- · Accelerate progress by attracting the best minds from the entire brain research community to research ALS and related disorders which share common underlying mechanisms;
- · Multiply impact by applying discoveries to a broader grouping of neurodegenerative diseases.

"We are incredibly grateful for all of the support and awareness for ALS in the last four months as a result of the ALS Ice Bucket Challenge. We know donors and our community will be pleased we have demonstrated strong stewardship of the gift we have received, and that, with the matching research funds from Brain Canada, the total impact of the ALS Ice Bucket Challenge is \$26 million".

-Tammy Moore, CEO, ALS Canada



From left to right: Ms. Inez Jabalpurwala, President and CEO, Brain Canada; Ms. Tammy Moore, CEO, ALS Society of Canada; Dr. Heather Durham, Chair of the Research Council, ALS Society of Canada; Mr. Brian Parsons (person living with ALS).

British Columbia Alzheimer's Research Award Program

The British Columbia Alzheimer's Research Award Program is a partnership of four organizations that came together to harness BC's vibrant research community, and fund research into Alzheimer's disease that currently affects over 700,000 Canadians.

- Brain Canada, the Michael Smith Foundation for Health Research (MSFHR), Genome British Columbia (Genome BC), and The Pacific Alzheimer Research Foundation (PARF) created a \$7.5-million fund to seek solutions to Alzheimer's disease and related dementias;
- In November of 2014, five multi-disciplinary teams were each awarded \$1.5 million funding over three years.

"This opportunity to invest in Alzheimer's disease research is extremely welcome particularly with the strong partnerships involved from British Columbia and Brain Canada. The application of research to making a difference to persons affected by this insidiously progressive neurodegenerative disorder is imperative and BC researchers will have an impact."

– B. Lynn Beattie President, The Pacific Alzheimer Research Foundation



From left to right: Dr. Alan Winter, President and CEO, Genome BC; Dr. Diane Finegood, President and CEO, Michael Smith Foundation for Health Research; Dr. B. Lynn Beattie, President, Pacific Alzheimer Research Foundation; and Dr. David Kaplan, Brain Canada Board Director.

CQDM and OBI "Focus on Brain"

Brain Canada, CQDM and the Ontario Brain Institute (OBI) launched a joint funding program to support the development of innovative tools, technologies and platforms to accelerate the discovery of new, safe and effective drugs for disorders of the brain and nervous system.

- The Focus on Brain program is a \$12.5-million partnership open to multi-disciplinary research teams linking researchers in Quebec with other Canadian researchers, and the academic sector with the small and medium-sized enterprise sector;
- This unique partnership hopes to develop strong collaborations between academic researchers and the pharmaceutical industry, and better align research with the needs of the industry;
- · To date, six multi-disciplinary teams have been awarded a total of \$8.4 million through this innovative program.

"We are delighted to partner with Brain Canada to launch our second pan-Canadian funding initiative to engage the best researchers throughout Canada in translational research, this time in the field of neuroscience. The drug discovery process in neuroscience is paved with major hurdles. Brain Canada's footprint in brain research, as well as its strong presence in Canada, are crucial elements to the success of this new funding initiative."

- Diane Gosselin, President and CEO of CQDM



From left to right: Dr. Diane Gosselin, President and CEO, CQDM; Dr. Rémi Quiron, Quebec Chief Scientist; Dr. Sam David, President of the Canadian Association for Neuroscience; Ms. Inez Jabalpurwala, President and CEO, Brain Canada.

Canadian Cancer Society Impact Grants

Brain Canada has partnered with the Canadian Cancer Society Research Institute to encourage and support more brain cancer research through

- The joint funding platform is designed to fund new research that will quickly adopt innovations and accelerate the application of new knowledge to address problems in brain cancer;
- This partnership between two leading research funders will result in increased investment in brain cancer research and encouraged collaboration between scientists from the cancer and neuroscience fields;
- The announced model will match funds raised from donors and partners of the Canadian Cancer Society Research Institute for a total investment of \$5 million.

"Brain cancer is the most common cause of cancer death in young children. There is a huge need for more research on brain cancers, both in children and adults, so that we can save people's lives and ensure that their lives are of good quality with minimal side effects of treatment. This money will help us to make real and significant progress against this disease. We are very grateful for the support from Brain Canada, as well as from our generous donors who are making this possible."

- Pamela Fralick, President and CEO, Canadian Cancer Society



From left to right: Ms. Inez Jabalpurwala, President and CEO, Brain Canada; Dr. Janet Rossant, Chief of Research, The Hospital for Sick Children; Dr. Uri Tabori, researcher and recipient of a grant, The Hospital for Sick Children; The Hon. Rona Ambrose, Minister of Health; Dr. Michael Taylor, researcher and recipient of a grant, The Hospital for Sick Children; Ms. Pamela Fralick President and CEO, Canadian Cancer Society; Mr. Carl Cadogan, CEO, Brain Tumour Foundation of Canada.

brain philanthropists.

Private donors and foundations are an important part of the brain community. Their philanthropy goes beyond making a financial donation: they are partners that can set program priorities by virtue of how they direct their giving. The Brain Canada public-private partnership funding model is a bottom-up approach whereby Brain Canada works closely with donors to design programs that match their interests in particular disease groupings or mechanisms. Government then matches their donations on a 1:1 basis. Through Brain Canada's open call process and reach to the entire brain research community, what gets funded is at the intersection of donor interests and the very best Canadian researchers and clinicians presenting novel, paradigm -changing ideas.

We would like to thank all of our generous, visionary private donors and foundations. We highlight four of them here.

Chaqnon Family

On December 21, 2012, a joint venture between the Chagnon Family of Quebec and Brain Canada was announced, to support novel and transformative intervention research that will improve the prevention of Alzheimer Disease and Related Disorders. To date, one Chagnon Family - Brain Canada Interventions for Prevention of Alzheimer Disease and Related Disorders team grant has been awarded. The team is receiving \$10 million over five years. This represents the largest single grant in the area of prevention of Alzheimer's disease ever made in Canada.

"Brain Canada seemed like the ideal organization with which to develop a research partnership that would produce credible and verifiable results. The Brain Canada team has demonstrated its professionalism, availability and openness. Together, the Chagnon family, Brain Canada and the Government of Canada are proud to be contributing \$10 million to this research project over a five-year period."

- André Chagnon, O.C., O.Q.



The Krembil Foundation

The Krembil Foundation has funded grants across Canada for a wide range of charitable purposes benefiting all Canadians. Their mandate is centered on helping people by supporting medical research and education, and they have made major contributions to research and to neuroscience research in particular, which are transforming the field. The Krembil Foundation is funding two MIRI teams focused on memory and on blindness. The total grant for these two teams is \$3 million over three years. The Foundation also provided funding to allow one of Brain Canada's Brain Repair Program teams to continue their research on uncovering the causes of Parkinson's Disease for an additional three years.

"Through their programs, Brain Canada has designed a platform that has the potential to create opportunity for countless scientific collaborations that will likely result in the discovery of many life altering medical breakthroughs. As long-time supporters of Brain Canada, we strongly believe in their efforts and recognize the benefits and leveraging opportunities the Canadian Brain Research Fund brings to our organization." - Mark Krembil, President, The Krembil Foundation Mr. Mark Krembil, President, The Krembil Foundation and Mrs. Stacy Krembil,

Director, The Krembil Foundation.

Listening to the voices of patients, families and caregivers.

The Azrieli Foundation

The Azrieli Foundation supports a wide range of initiatives and programs in the fields of education, architecture and design, Jewish community, Holocaust commemoration and education, scientific and medical research, and the arts.

In 2012, a partnership between the Azrieli Foundation and Brain Canada was announced. Through this joint venture, the partners aim to support excellent translational research in the area of neurodevelopmental disorders, with a special focus on Autism Spectrum Disorder and Fragile X syndrome. The Foundation donated \$4.25 million to Brain Canada, which was matched by the Government of Canada to fund four Azrieli Neurodevelopmental Research Program team grants under the MIRI program (total grant support \$8.7 million over five years). In 2014 the Foundation increased their support by \$3.25 million, and in December of 2014, the second phase of the Azrieli Neurodevelopmental Research Program was launched. This second program has an emphasis on linking Canadian researchers with international collaborators. The Azrieli Foundation's generous commitment is the largest private donation to date to support neurodevelopmental research – \$7.5 million, matched for a total of \$15 million.

"We know that Canada is home to some of the world's foremost neuroscientists and that we have the potential to be a world leader in neurodevelopmental research. By providing scientists with significant financial support, we are providing the lifeblood of advanced research."

- Naomi Azrieli, Chair and CEO, The Azrieli Foundation



Dr. Naomi Azrieli, Chair and CEO, The Azrieli Foundation and Dr. Nahum Sonenberg, recipient of an Azrieli Brain Canada MIRI grant.

The W. Garfield Weston Foundation

The W. Garfield Weston Foundation has a long legacy of supporting medical research going back to the 1960s. The Foundation was one of the early contributors to Brain Canada following the announcement of the Canada Brain Research Fund and, in 2011, provided \$3 million to enable Brain Canada to launch the first MIRI grant program. With the match, \$6 million was made available, and with additional funding from the Krembil Foundation, five grants were awarded in April 2013. Each team is receiving \$1.5 million over three years. The teams include researchers from among Canada's top universities, hospitals and institutes, pursuing novel, transformative research aimed at improving our understanding of human nervous system function and dysfunction, and its impact on health.

"Brain Canada has an outstanding track record of funding breakthroughs in neuroscience. We are delighted to be the first to support Brain Canada, and are confident the research of these five exceptional teams will benefit the millions of Canadian patients and caregivers affected by brain disorders. This program continues our long history of support for medical research, from funding the Banting and Best Institute in the 1960s to the new Dalglish Family Hearts & Minds Clinic."

> - W. Galen Weston, Chairman and President The W. Garfield Weston Foundation



From left to right: Mr. Rupert Duchesne, Chair, Brain Canada, The Hon. Hilary M. Weston, Mr. W. Galen Weston, Ms. Claudia Hepburn, The Hon. Leona Aglukkag, Former Minister of Health, Mr. Robert Vaux, Ms. Wendy Rebanks, Ms. Inez Jabalpurwala, President and CEO, Brain Canada.

other partnerships.

In addition to our partnerships through the Canada Brain Research Fund, Brain Canada is proud of our longstanding relationships with both the Barbara Turnbull Foundation and the van Tol family.

Barbara Turnbull Award for Spinal Cord Research

This award, in support of Canadian research on spinal cord injury, is funded by the Institute of Neurosciences, Mental Health and Addiction (INMHA) of the Canadian Institutes of Health Research (CIHR) in partnership with Brain Canada and the Barbara Turnbull Foundation, and is valued at \$50,000. From among CIHR-funded investigators, the award recipient is selected to be conducting the most promising and exciting spinal cord research. The 2014 award went to Dr. Yves De Koninck at Université Laval for his project entitled "Plasticity of inhibition in spinal sensory pathways".

"I am deeply honoured to receive this award. Barbara Turnbull's courage and relentless advocacy efforts to promote spinal cord research are an inspiration to us all and I sincerely hope our work will have a significant impact on the development of therapeutic strategies to alleviate chronic pain, a terrible condition that afflicts the majority of patients with spinal cord injury and is reported as their most prevalent subject of grievance."

- Yves De Koninck, Université Laval



From left to right: Ms. Barbara Turnbull, President, Barbara Turnbull Foundation; Dr. Yves De Koninck. Université Laval: Ms. Inez Jabalpurwala, President and CEO. Brain Canada; Dr. Nathalie Gendron, Assistant Director, INMHA.

Dr. Hubert van Tol Travel Fellowship

The neuroscience community lost a brilliant, well-respected scientist when Dr. Hubert van Tol died suddenly in a bicycle accident on April 20, 2006. To honour him, his family set up the Dr. Hubert van Tol Fund at Brain Canada, through which the Dr. Hubert van Tol Travel Fellowship was established. The fund has received more than \$30,000 in donations since it was established. The \$5,000 fellowship enables Ph.D. students and postdoctoral fellows performing research as part of a Brain Canada MIRI team or Training award to attend major international conferences, symposia or training courses. The 2014 Dr. Hubert van Tol Award was awarded to Ms. Nancy Butcher, a doctoral candidate who is conducting research using advanced brain imaging techniques to measure levels of the brain chemical dopamine, to differentiate between Parkinson's disease and other motor neuron defects.

"Brain imaging is a critical tool in my research investigating antipsychotic treatment side effects in patients with schizophrenia at the Centre for Addiction and Mental Health. Through the support of the Dr. Hubert van Tol Travel Fellowship, I had the opportunity to attend a course on positron emission tomography (PET) pharmacokinetics and data analyses, where I trained with world experts in the latest imaging methods and analytic techniques. I believe this training was invaluable to the successful completion of my PET neuroimaging project for my doctoral studies and will provide a platform for further developing my career as a scientist in mental health research."

- Nancy Butcher, University of Toronto



Ms. Nancy Butcher, University of Toronto, and supervisor Dr. Anne Bassett, Professor of Psychiatry, University of Toronto.

brain canada in the world.

It is important for Brain Canada to connect with the global brain community, to share the public-private partnership model, seek opportunities to further leverage funds and ideas, and ensure that Canadian researchers continue to make important contributions to advancing brain initiatives around the world.

Below are a few of the global events in 2014 where Brain Canada had a presence:



Global action against dementia legacy summits were ignited by discussions held at the G8 Summit on Dementia in London. UK on Dec 11, 2013. The goals of these legacy events are to explore collaborative opportunities for research into novel diagnostic, pre-emptive and therapeutic approaches, and new models of care for dementia by bringing together academia and industry; provide a better understanding of the impact of the paradigm shift in pharmaceutical research on the development of new treatments against dementia; and to foster a collective approach to problem solving through the pooling and sharing of resources. The first legacy event on finance and social investment was held in London, UK on June 19, 2014.

Inez Jabalpurwala, Brain Canada's President and CEO, gave a presentation outlining the public-private partnership model. the impact of the model on the philanthropic space for brain research support, and how these investments will achieve maximum impact. The second legacy event, cohosted by the French National Alliance for Life Sciences and Health (AVIESAN) and the Canadian Institutes of Health Research (CIHR), was held on September 11, 2014 in Ottawa, Canada. Ms. Jabalpurwala provided the opening remarks about Canada's contributions to the global effort, its leadership in brain health and research, and introduced Canada's Minister of Health, The Honourable Rona Ambrose.

Changing the Global Care for Alzheimer's and Dementia was a conference co-hosted by the American Association for Retired Persons and the Global CEO Initiative on Alzheimer's disease. Ms. Jabalpurwala gave a presentation outlining the public-private partnership model, the impact of the model on the philanthropic space for brain research support, and how these investments contribute to the research environment addressing the challenges of Alzheimer's disease and dementia.

Brain Canada is proud to be a member of the following international initiatives: Global CEO Initiative on Alzheimer's disease; Institute of Medicine Forum on Neuroscience and Nervous System Disorders; and the International Alzheimer's Disease Funders Consortium.

thanks to our supporters.

With the launch of the Canada Brain Research Fund (CBRF) public-private partnership, Brain Canada embarked on a \$100-million, national fundraising campaign. All funds raised from private and non-governmental sources will be matched by Government on a 1:1 basis. The fundraising total to date is over \$85 million.

Brain Canada encourages all organizations raising funds for brain research to either contribute directly to the CBRF and have their donor dollars matched, or to partner on research programs to further leverage the public-private match.

Brain Canada has always taken pride in keeping non-research related expenses to the minimum required for operational efficiency and good governance. Brain Canada Directors have also made generous gifts to operations. Through these efforts, \$0.85 to \$0.90 of every dollar raised is disbursed directly to Canadian researchers.

We thank the lead donors listed below and all of our other donors across the country.

Individuals and private Foundations

Lead donors

The Chaqnon Family - \$12.5 million The Azrieli Foundation - \$7.5 million The W. Garfield Weston Foundation - \$3 million The Krembil Foundation - \$1 million

\$100,000 - \$249,000

The Max Bell Foundation The Jim Pattison Foundation The Rotman Family Foundation The Lawrence and Judith Tanenbaum Foundation

\$50,000 - \$99,999

Michael H. Wilson

\$25,000 - \$49,999

Rupert Duchesne Marianne Seger Allan R. and Shirley Taylor The Henry and Berenice Kaufmann Foundation

The Barbara Turnbull Foundation

\$10,000 - \$24,999

The Ira Gluskin & Maxine Granovsky Gluskin Charitable Foundation The Hon. John and Mrs. Joan MacKenzie

Corporations

\$600,000 **RBC** Foundation

\$500.000 Bell Canada CIBC

\$200,000

National Bank of Canada

\$100,000

Power Corporation of Canada

Gifts were made to honour

Donald B. Basarsky Eric Clarke Michel Lanot Violet Jeeves Lecavalier Helen Lord Betty Martin Shannon Peden Rolland Therrien Randall Troppmann

board of directors.

An independent Board of Directors with distinguished members drawn from the business, science, and academic communities.

Patron

(NeuroScience Canada Partnership) His Excellency the Right Honourable David Johnston, C.C., C.M.M., C.O.M., C.D.

Governor General of Canada (Ottawa)

Honorary Chair

Michael H. Wilson, P.C., C.C.

Chairman Barclays Canada; Former Canadian Ambassador to the United States of America (Toronto)

Chair of the Board

Rupert Duchesne

Chair, Executive Committee **Group Chief Executive** Aimia (Montreal)

Directors

The Hon. W. David Angus, Q.C., Ad. E. Former Member, Senate of Canada

(Montreal)

Naomi Azrieli, Ph.D. (From June 2015) Chair and CEO The Azrieli Foundation (Montreal)

Vincent Castellucci, Ph.D.

Professor Emeritus Faculty of Medicine Université de Montréal (Montreal)

Max S. Cynader, CM, O.B.C, Ph.D., FRSC,

Director of the Brain Research Centre Vancouver Coastal Health Research Institute and University of British Columbia (Vancouver)

Lili de Grandpré

Chair, Governance, Nominating and Ethics Committee Managing Director CenCEO Consulting (Montreal)

Inez Jabalpurwala

President and CEO Brain Canada Foundation and NeuroScience Canada Foundation (Montreal)

David Kaplan Ph.D.

Senior Scientist, Cell Biology Program The Hospital for Sick Children; Canada Research Chair in Cancer and Neuroscience; University of Toronto (Toronto)

Robert Mark Krembil

Chair, Audit, Finance and Investment Committee President The Krembil Foundation (Toronto)

Brandt C. Louie, O.B.C.

Chairman and CEO H. Y. Louie Limited; Chairman of the Board London Drugs Limited (Vancouver)

Lawrence Tanenbaum, O.C.

Chairman and CEO Kilmer Van Nostrand Co. Ltd.; Chairman Maple Leaf Sports & Entertainment Ltd. (Toronto)

Allan R. Taylor, O.C. (To June 2015) Retired Chairman and CEO Roval Bank of Canada (Toronto)

Franco J. Vaccarino, Ph.D.

Chair, Research and Policy Committee President University of Guelph (Guelph)

Samuel Weiss, Ph.D.

Professor and Director Hotchkiss Brain Institute University of Calgary (Calgary)

Catherine Zahn, M.D., F.R.C.P.(C), M.HSc, O.C.

President and CEO Centre for Addiction and Mental Health (Toronto)

Honourary Board Members

Albert J. Aguayo, O.C., M.D., FRSC

Emeritus Professor, and Former Director, Centre for Research in Neuroscience, McGill University, Montreal General Hospital Research Institute (Montreal)

Rick Hansen, C.C., O.B.C.

President and CEO Rick Hansen Man in Motion Foundation and Rick Hansen Institute (Vancouver)

Ronald N. Mannix, O.C.

Coril Holdings Ltd. (Calgary)

Heather Munroe-Blum, O.C., O.Q., Ph.D., FRSC

Former Principal and Vice-Chancellor McGill University (Montreal)

J. Robert S. Prichard, O.C., O.Ont., Ph.D.(Hon.), LL.D.

Chair, Metrolinx Chairman, Torys LLP President Emeritus, University of Toronto (Toronto)

Richard B. Stein. Ph.D.

Professor Emeritus of Physiology and Neuroscience Centre for Neuroscience University of Alberta (Edmonton)

John M. Stewart, LLB

Former Partner Blake Cassels & Graydon LLP (Toronto)

Allan R. Taylor, O.C. (From June 2015) Retired Chairman and CEO Royal Bank of Canada (Toronto)

Barbara Turnbull

President, The Barbara Turnbull Foundation for Spinal Cord Research (Toronto)

Dave Williams, M.D.

Canadian Astronaut President and CEO South Lake Regional Health Centre (Newmarket)

science advisory council.

Provides key input to Brain Canada in the form of intelligence about developments in the field, in Canada and internationally, and a broad assessment of Brain Canada's research program.

Chair

Freda Miller, Ph.D.

Senior Scientist, Neurosciences & Mental Health Hospital for Sick Children Professor, Department of Molecular Genetics University of Toronto (ON) Canada Research Chair in Developmental Neurobiology

Area of expertise: Development

Canadian Members

Yves De Koninck, Ph.D.

Professor of Psychiatry & Neuroscience, Laval University Adjunct Professor of Pharmacology & Therapeutics, McGill University Director, Division of Cellular & Molecular Neuroscience, Institut universitaire en santé mentale de Québec (QC) Scientific Director, Quebec Pain Research Network Area of expertise: Neural Excitability, Synapses, and Glia: Cellular Mechanisms

Jacques Drouin, D. Sc., MRSC

Director, Molecular Genetics research unit, IRCM Full Researcher Professor, Department of Biochemistry, Université de Montréal Adjunct Professor, Department of Anatomy and Cell Biology and Department of Biochemistry, McGill University (QC)

Area of expertise: Integrative Systems: Neuroendocrinology, Neuroimmunology and Homeostatic Challenge

Alan C. Evans, Ph.D.

Professor, departments of Neurology and Neurosurgery, Biomedical Engineering, Medical Physics, McGill University (QC) Area of expertise: Disorders of the Nervous System

Lesley K. Fellows, M.D., DPhil

Associate Professor, Department of Neurology & Neurosurgery Montreal Neurological Institute (QC)

Area of expertise: Neurology

Kurt Haas, Ph.D.

Associate Professor, Department of Cellular and Physiological Sciences University of British Columbia (BC) Area of expertise: Model organisms and systems International Members

Sheena Josselyn, Ph.D. Senior Scientist, Neurosciences & Mental Health Program, Hospital for Sick Children Research Institute; Canada Research Chair in Molecular and Cellular Cognition Associate Professor, Department of Physiology Institute of Medical Science University of Toronto (ON) Area of expertise: Cognition and Behaviour

James L. Kennedy, MSc, M.D., FRCP(C), FRSC

Director of the Neuroscience Research Department and Head of the Psychiatric Neurogenetics Section, Centre for Addiction and Mental Health (CAMH) (ON) Area of expertise: Genetics

Bryan E. Kolb, Ph.D.

Professor, Department of Neuroscience, University of Lethbridge (AL) Area of expertise: Cognition and behaviour

Stan Kutcher, M.D., FRCPC, FCAHS

Sun Life Financial Chair in Adolescent Mental Health Professor, Department of Psychiatry, Dalhousie University (NS) Area of expertise: Cognition and behaviour

Brian MacVicar, Ph.D.

Professor, Dept. of Psychiatry, University of British Columbia (BC) Area of expertise: Neural Excitability, Synapses and Glia, Cellular Mechanisms

Doug P. Munoz, Ph.D. Professor of Physiology, Psychology

and Medicine Queen's University (ON) Director, Queen's Centre for Neuroscience Studies Canada Research Chair in Neuroscience Area of expertise: Sensory and Motor Systems

Rachel F. Tyndale, Ph.D.

Professor, Department of Pharmacology & Toxicology University of Toronto Endowed Chair in Addictions, Department of Psychiatry University of Toronto Head Pharmacogenetics, Centre for Addiction and Mental Health (CAMH) (ON) Area of expertise: Addiction

International Members

Karl Deisseroth, M.D., Ph.D.

D.H. Chen Professor of Bioengineering and of Psychiatry and Behavioral Sciences, Stanford University, Howard Hughes Medical Institute (CA, USA) Area of expertise: Psychiatry/Behavior/Leader in optogenetics

Arnold Kriegstein, M.D., Ph.D.

Director, Eli and Edy, the Broad Center of Regeneration Medicine and Stem Cell Research, Department of Neurology, UCSF School of Medicine (CA, USA)

Area of expertise: Development/photonics, Neural Stem Cells and Embryonic Cortical Development

Lorne Mendell, Ph.D.

Distinguished Professor, Stony Brook University (NY, USA)

Area of expertise: Pain, neuroplasticity of the mammalian spinal cord

Klaus-Armin Nave, Ph.D.

Head Max-Planck Gottingen, Glial biology and neurodegeneration, Max Planck Institute for Experimental Medicine, Göttingen (GER) Area of expertise: Glial biology and neurodegeneration

Bill Newsome, Ph.D.

Arman Family Provostial Professor and Professor of Neurobiology and, by courtesy, of Psychology, Stanford School of Medicine (CA, USA) Area of expertise: Visual perception and visually-based cognition, neural mechanisms of decision making

Angela Roberts, Ph.D.

Professor of Behavioural Neuroscience. Department of Physiology, Development and Neuroscience, Cambridge (UK) Area of expertise: Prefrontal cortex/behavior/ psychiatric diseases

Bruce Rosen, M.D., Ph.D.

Professor of Radiology at the Harvard Medical School Professor of Health Science and Technology at the Harvard-MIT Division of Health Sciences and Technology, Director of the Athinoula A. Martinos Center for Biomedical Imaging at Massachusetts General Hospital (MA, USA) Area of expertise: World leading expert in functional neuroimaging

Rosalind Segal, M.D., Ph.D.

Professor of Neurobiology, Dana Farber Cancer Institute, Harvard (MA, USA) Area of expertise: Cellular and molecular neuroscience/oncology

D James Surmeier, Ph.D.

Chair, Department of Physiology, Nathan Smith Davis Professor of Physiology, Northwestern (IL, USA) Area of expertise: Basal ganglia/cell metabolics and neurodegenerative disease; Molecular Biology; Movement Disorders; Neuroscience; Parkinson's disease; Physiology; Schizophrenia

Li-Huei Tsai, Ph.D.

Director, The Picower Institute for Learning and Memory, Picower Professor of Neuroscience, Department of Brain and Cognitive Sciences, Senior Associate Member,

Broad Institute, Massachusetts Institute of Technology, Department of Brain and Cognitive Sciences, Picower Institute for Learning and Memory (MA, USA)

Area of expertise: Neurodegeneration

thanks to Allan R. Taylor.



Mr. Allan R. Taylor (bottom row, second from right), surrounded by Brain Canada Directors and staff, at our June 3, 2015 Annual General Meeting.

On June 3, 2015, Allan R. Taylor stepped down from the Board of Brain Canada, after nearly 20 years as a dedicated volunteer. Over that period, Mr. Taylor served in different capacities, including as Chair of the Board, and as Chair of the Governance, Nominating and Ethics Committee. As one of Canada's most trusted and accomplished leaders, he spent his professional career at RBC, rising to the office of the Chairman and CEO. He has always given back to his community, whether on non-profit boards or as a champion of corporate philanthropy and increased Government investments in research.

Mr. Taylor's contributions to Brain Canada have been enormous; his leadership on governance was central to our transformation from the NeuroScience Network Centre of Excellence to the NeuroScience Canada Partnership and Foundation, and to the present Brain Canada Foundation. In 2006, this excellence in governance was recognized when we received The Conference Board of Canada/Spencer Stuart National Awards in Governance award in the non-for-profit category.

Mr. Taylor often says that good governance is the foundation upon which a vision becomes a reality. For those of us who have had the great privilege of being part of Brain Canada during the era of Mr. Taylor, we are most grateful that he helped to build our solid foundation, which positioned us well for a partnership with the Government of Canada.

Thank you Mr. Taylor; everyone touched by this organization owes a great deal to you, and you will always be part of our future success.

financial report.

NeuroScience Canada Partnership **Brain Canada Foundation**

Combined Financial Statements

At December 31	2014 \$	2013
ASSETS		
Current Assets		
Cash and cash equivalents	6 116 134	5 182 679
Short term investments,		
including accrued interest	29 609 021	28 816 530
Other receivables	67 769	45 496
Prepaids and deposits	7 735	97 566
	35 800 659	34 142 271
Computers, software,		
furniture and equipment	101 183	5 733
	35 901 842	34 148 004
Accounts payable and accrued liabilities Salaries and benefits payable Deferred contributions	84 726 102 550 26 329 306	35 514 125 228 10 291 035
	26 516 582	10 451 777
Non-current liabilities		
Deferred contributions	9 278 494	23 589 158
	35 795 076	34 040 935
NET ASSETS		
Unrestricted net assets	5 583	101 336
Invested in capital assets	101 183	5 733
	106 766	107 069
	35 901 842	34 148 004

Excess of expenditures over revenues	(303)	(304)
Total Expenditures	10 291 338	3 716 227
Amortization	13 608	2 429
Operating expenses	1 779 298	1 634 573
EXPENDITURES Grants and awards	8 498 432	2 079 225
Total Revenues	10 291 035	3 715 923
Interest income	18 439	4 677
	10 272 596	3 711 246
Add amount recognized	1 232 629	935 216
REVENUES Contributions	9 039 967	2 776 030
		Ψ
For the year ended December 31	2014 \$	2013

The financial statements of NeuroScience Canada Partnership and Brain Canada Foundation are audited by KPMG LLP and are available upon request.

remembering Barbara Turnbull.



Barbara Turnbull

Everyone at Brain Canada was deeply saddened by the death of Barbara Turnbull on May 10th, 2015.

Through her foundation, The Barbara Turnbull Foundation for Spinal Cord Research, Barbara was Brain Canada's longest-standing partner, and believed in this organization and supported us from the beginning. She was a guiding light who inspired us and taught us that life is a gift that we too often take for granted, and that how we deal with adversity is the real test of our character. And yet, she was never impatient with those who failed to act with the same grace, kindness and courage as she always showed. She reminded us that research must serve people, and that every discovery along the way to a cure carries the potential of improving lives.

Barbara brought joy and optimism to all among us who had the privilege of knowing her. She made our lives better. She made us better. She will be missed beyond words. Our thoughts and prayers are with her devoted and loving family.





one brain. one community in action.

The front cover features researchers, paramedics, a donor and other participants involved in *The Frontier Trial - Field Randomization of NA-1 Treatment in Early Responders* project, one of the recipients of a 2014 Brain Canada Multi-Investigator Research Initiative grant. This project advances a key scientific discovery from "bench to curbside" by putting a drug discovered in the lab into the hands of front line paramedics. This drug, when administered by paramedics in the critical early timeframe following a stroke, has the potential to reduce the consequences of a stroke by up to 50%.

From left to right:

- Ms. Kate Byrne, Research Program Manager, Rescu;
- Mr. Mark Krembil, Brain Canada donor, Brain Canada and NoNO Inc. Board Director;
- Dr. Michael Salter, co-founder and Vice President, Finance of NoNO Inc.;
- Dr. Laurie Morrison, Professor and Clinician Scientist, University of Toronto, Director, Rescu;
- Dr. Richard Verbeek, Hospital Medical Director, Toronto EMS Primary Care Paramedic Program and Toronto Fire Service Emergency Patient Care Program;
- Mr. Adam Byers, Research Coordinator, Rescu;
- Ms. Ellen Ironside, Peel Regional Paramedic Services;
- Ms. Ornella Guizzo, Toronto Paramedic Services;
- Ms. Tatyana Yavorska, Research Assistant, Rescu.